{"id":"fosamprenavir-gw433908","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1664","moleculeType":"Small molecule","molecularWeight":"585.62"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amprenavir works by inhibiting the protease enzyme, which is necessary for the replication of retroviruses such as HIV. By blocking this enzyme, amprenavir prevents the virus from replicating and reduces the viral load in the body.","oneSentence":"Fosamprenavir is a prodrug that is metabolized into amprenavir, a protease inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:17.808Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of HIV-1 infection in adults and children"}]},"trialDetails":[{"nctId":"NCT04383262","phase":"PHASE2","title":"Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-04-01","conditions":"Laryngopharyngeal Reflux","enrollment":104},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT06704100","phase":"PHASE2","title":"Oral Fosamprenavir + Sodium Alginate for GERD","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00071760","phase":"PHASE2","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-10-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":59},{"nctId":"NCT00028366","phase":"NA","title":"Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT00977301","phase":"PHASE1","title":"Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-11","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00817765","phase":"PHASE1","title":"Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-01","conditions":"HIV Infection, Fungal Infection","enrollment":24},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT00094523","phase":"PHASE3","title":"Fosamprenavir Versus Other Protease Inhibitors","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-12-14","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":314},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01077557","phase":"","title":"Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2006-11","conditions":"Fracture, Infection, Human Immunodeficiency Virus","enrollment":1},{"nctId":"NCT01077635","phase":"","title":"PENTA Fosamprenavir Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-10","conditions":"Infection, Human Immunodeficiency Virus","enrollment":1},{"nctId":"NCT00242840","phase":"PHASE3","title":"Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-06","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":20},{"nctId":"NCT00935480","phase":"PHASE3","title":"IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2010-10","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT00089583","phase":"PHASE2","title":"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-07","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":110},{"nctId":"NCT00040664","phase":"PHASE2","title":"A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-07","conditions":"HIV Infection","enrollment":69},{"nctId":"NCT01209065","phase":"PHASE1","title":"GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-09","conditions":"Infections, Human Immunodeficiency Virus and Herpesviridae","enrollment":27},{"nctId":"NCT00240552","phase":"PHASE4","title":"Fosamprenavir Expanded Access","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":85},{"nctId":"NCT01348308","phase":"PHASE3","title":"Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-09","conditions":"HIV-1 Infection, AIDS","enrollment":407},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00764465","phase":"PHASE2","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-10","conditions":"Healthy","enrollment":45},{"nctId":"NCT00802074","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-12","conditions":"Healthy","enrollment":45},{"nctId":"NCT00614991","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01384682","phase":"PHASE4","title":"Maraviroc Switch Collaborative Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV","enrollment":399},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT02486510","phase":"EARLY_PHASE1","title":"Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication","status":"TERMINATED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2012-07","conditions":"HIV-1 Infection","enrollment":7},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01222611","phase":"PHASE4","title":"HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-03","conditions":"Chronic HIV Infection, HCV Coinfection","enrollment":42},{"nctId":"NCT00877591","phase":"PHASE1","title":"Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"Opioid Dependency, HIV Infections","enrollment":63},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00242216","phase":"PHASE4","title":"\"The Once A Day Protease Inhibitor Regimens\"","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2004-05","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT00148785","phase":"PHASE4","title":"A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-07","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00727597","phase":"PHASE3","title":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infections","enrollment":101},{"nctId":"NCT00335270","phase":"PHASE4","title":"A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-03","conditions":"HIV","enrollment":100},{"nctId":"NCT01054586","phase":"","title":"Fosamprenavir in Pts With Hepatic Impairment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":167},{"nctId":"NCT00296504","phase":"PHASE3","title":"A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2001-11","conditions":"Infection, Human Immunodeficiency Virus","enrollment":753},{"nctId":"NCT00043888","phase":"PHASE3","title":"Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00966329","phase":"PHASE4","title":"Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV, HIV Infections","enrollment":30},{"nctId":"NCT01450618","phase":"","title":"Comparative Tolerability of Protease Inhibitors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"HIV","enrollment":26000},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00450580","phase":"PHASE3","title":"HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2007-03","conditions":"Infection, Human Immunodeficiency Virus I, HIV-1 Infection","enrollment":212},{"nctId":"NCT01010399","phase":"PHASE4","title":"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects","status":"COMPLETED","sponsor":"Felizarta, Franco, M.D.","startDate":"2009-09","conditions":"Hypertriglyceridemia, HIV Infection","enrollment":36},{"nctId":"NCT00122603","phase":"PHASE2","title":"Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-12","conditions":"HIV Infections","enrollment":61},{"nctId":"NCT01054638","phase":"","title":"HIV Treatment and CVD Events","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"HIV Infection, Cardiovascular Disease, Infection, Human Immunodeficiency Virus","enrollment":""},{"nctId":"NCT01290211","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-04","conditions":"Healthy","enrollment":28},{"nctId":"NCT00085943","phase":"PHASE3","title":"KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":866},{"nctId":"NCT01140412","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-07","conditions":"Healthy","enrollment":14},{"nctId":"NCT00775125","phase":"PHASE1","title":"VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-06","conditions":"Hepatitis C, Telaprevir, HIV","enrollment":40},{"nctId":"NCT00363142","phase":"PHASE3","title":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":211},{"nctId":"NCT00481182","phase":"PHASE1","title":"Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT00144833","phase":"PHASE3","title":"Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"HIV-1","enrollment":150},{"nctId":"NCT00025727","phase":"PHASE3","title":"Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure","status":"UNKNOWN","sponsor":"GlaxoSmithKline","startDate":"2001-05","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT00008554","phase":"PHASE3","title":"Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy","status":"UNKNOWN","sponsor":"Glaxo Wellcome","startDate":"2000-11","conditions":"HIV Infections","enrollment":210},{"nctId":"NCT00009061","phase":"PHASE3","title":"Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs","status":"UNKNOWN","sponsor":"Glaxo Wellcome","startDate":"2000-11","conditions":"HIV Infections","enrollment":624}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"fosamprenavir (GW433908)","genericName":"fosamprenavir (GW433908)","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosamprenavir is a prodrug that is metabolized into amprenavir, a protease inhibitor. Used for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}